NJ Bio is proud to announce its participation in the upcoming TIDES Europe Conference, taking place in Basel, Switzerland, from November 11–13, 2025, alongside the Sapala team. Through the years, this event has become a premier global platform for innovation in oligonucleotide and peptide therapeutics, bringing together industry leaders from around the world to explore advancements in oligos, peptides, mRNA and drug delivery. This year’s conference will feature over 100 expert speakers and 60 exhibitors, highlighting advancements and sharing insights across oligos and peptide -therapeutic discovery, preclinical and clinical development, manufacturing, mRNA therapeutics, genome editing, and macromolecular drug delivery.
NJ Bio’s CEO, Dr. Naresh Jain, will be delivering a presentation titled – “Optimizing Oligo-Protein Conjugates with Chemistry-Driven Solutions for Enhanced Properties and Scale-Up.” His talk will explore the use of protein-based conjugates for delivering oligonucleotides, the challenges in synthesis, analytical characterization, and scale-up due to the complex structure and chemistry of these therapeutics as well as the chemistry-driven strategies to overcome these hurdles. He will also share his insights on the role of advanced analytical techniques and rational linker design in optimizing key properties and enabling successful scale-up.
NJ Bio will be attending the upcoming conference alongside Sapala, a leading CDMO specializing in nucleic acid chemistry and oligonucleotides. Sapala is renowned for its niche expertise in amidites and DDS. Attendees can visit booth #130 to gain insights into their specialized expertise and explore opportunities for collaboration in oligonucleotide development.
With a comprehensive agenda of workshops, sessions, and networking opportunities, TIDES Europe 2025 is set to make a significant impact on the future of oligo and peptide therapeutics. Don’t miss out, register today: https://informaconnect.com/tides-europe/